Eisbach Bio GmbH

Do you want to learn more about our clinical results, our upcoming first-in-class ALC1 inhibitor Phase I/II trial and our transformative allosteric drug discovery engine? Meet Eisbach’s CEO Dr. Adrian Schomburg at ASCO in Chicago. #ASCO2024 #Oncology #ClinicalTrials #DrugDiscovery American Society of Clinical Oncology (ASCO)

🚀 Exciting News from Eisbach Bio! 🚀 We're thrilled to announce the completion of our Phase I clinical trial for our helicase inhibitor, EIS-10700, which demonstrated excellent safety, tolerability, and pharmacokinetics! 🌟 This marks the successful end of our first clinical study and we look forward to investigating the efficacy of EIS-10700 in oncology in the near future. Read the press release to learn more about the trial and stay tuned as we continue to push the boundaries of cancer medicine and synthetic lethality!💡 Link to PR: https://lnkd.in/eTC65FeW #Biotech #Pharma #ClinicalTrials #SyntheticLethality #CancerResearch #AIinMedicine

🔬 28 hours for a 100K High Throughput Screen 🌍 Imagine conducting a High Throughput Screening (HTS) of a 100K compound library with just 3 tip boxes! Sounds impossible, right? Our dedicated team at Eisbach Bio GmbH successfully conducted an entire HTS of a 100K compound library in 28 hours, using a full kinetic readout and using only 3 tip boxes. This feat not only underscores our commitment to efficiency but also to sustainability. 🌿 A big shout-out to the entire Eisbach team for their unwavering commitment and for making this seemingly impossible task possible. Special thanks to the reliable INTEGRA Biosciences pipetting robots and BMG LABTECH plate reader for their indispensable role in this achievement. By the way, read more on our recent IND clearance from FDA here: https://lnkd.in/eTC65FeW #Eisbach #HTS #Oncology #Innovation #Teamwork

🏔️ EIS-12656 Receives FDA IND Clearance: Celebrating with a Mountain Retreat 🏔️ Last week, our groundbreaking drug candidate, EIS-12656, received IND clearance from the FDA. To commemorate this milestone, the Eisbach Bio GmbH team embarked on a relaxing hike up to a picturesque mountain hut, nestled in the heart of the German Alps. 🥾 We strengthened our team bonds and returned with fresh enthusiasm to tackle the unmet oncology challenges ahead. 🙌 The team is grateful for this refreshing experience and can’t wait for more adventures together. 🏞️ Now, let’s play a guessing game: How long did the hike to the hut take team Eisbach to complete? (Hint: we started in Garmisch-Partenkirchen at 708 meters and ended at the elevation in the picture) Read more on the IND clearance here: https://lnkd.in/eTC65FeW #TeamBonding #EisbachBio #Eisbach #DrugDiscovery #Biotech

The FDA has granted Eisbach Bio GmbH IND approval for its drug candidate EIS-12656 👏 the world's first small molecule #therapy targeting the molecular machine ALC1, which is key #DNA damage and repair in several solid tumor indications. The superior #safety profile of EIS-12656, its brain penetrance and the non-overlapping resistance mechanisms with PARP inhibitors promise to transform #cancer therapy and enable the full potential of synthetic lethal drugs in the #clinic 💊. This marks Eisbach’s first #IND with the FDA for a drug candidate that emerges from our allosteric discovery engine 🏄♂️. We look forward to many more innovative products to come and to the start of our combined Phase I/II study 👩⚕️. Learn more: https://lnkd.in/eTC65FeW

Eisbach is excited to announce a $4.5 million investment from the Cancer Focus Fund to support its first-in-human Phase 1/2 Trial of EIS-12656 for refractory advanced solid #tumors. The trial at The University of Texas MD Anderson Cancer Center will enable the potential of synthetic lethality by developing novel drugs to exploit #molecular vulnerabilities. “Eisbach Bio GmbH’s distinctive and scientifically sophisticated approach to addressing common difficult-to-treat #cancers aligns perfectly with our goals at Cancer Focus Fund,” said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund. More information on the full press release under this link: https://lnkd.in/eTC65FeW #CancerResearch #ClinicalTrials #TeamEisbach #Oncology

Eisbach is excited to announce a $4.5 million investment from the Cancer Focus Fund to support its first-in-human Phase 1/2 Trial of EIS-12656 for refractory advanced solid #tumors. The trial at The University of Texas MD Anderson Cancer Center will enable the potential of synthetic lethality by developing novel drugs to exploit #molecular vulnerabilities. “Eisbach Bio GmbH’s distinctive and scientifically sophisticated approach to addressing common difficult-to-treat #cancers aligns perfectly with our goals at Cancer Focus Fund,” said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund. More information on the full press release under this link: https://lnkd.in/eTC65FeW #CancerResearch #ClinicalTrials #TeamEisbach #Oncology

🌟 Welcoming Deepak: Our Newest Protein Scientist 🌟 We are excited to announce the newest addition to our team at Eisbach Bio GmbH! Deepak Deepak, PhD joins us as a Protein Scientist, bringing unparalleled expertise in protein #biochemistry and X-ray protein crystallography. 👨🔬 Dive into Discovery: With a Ph.D. from LMU Munich – Ludwig-Maximilians-Universität München, Deepak's research prowess promises to greatly increase our understanding of protein interactions with small molecule inhibitors, paving new pathways for drug development in #oncology. 🎓 Academic Background: Deepak's journey is marked by groundbreaking work on the structural basis of interaction between DNA binding proteins & DNA mimic foldamers. Notably, he solved the first crystal structure of a DNA mimic foldamer in complex with Sac7d, a DNA binding protein. ⚡ Fun Facts: Fluent in 5 languages, Deepak fosters cross-cultural collaborations in scientific endeavors. Additionally, his passion for higher education shines through his #mentorship of hundreds of emerging scholars worldwide. Curious to learn more about Deepak Deepak, PhD's research and linguistic talents? Connect with him and let's embark on innovative ventures together! #Protein #Cancerresearch #biochemistry #Eisbachbio

🎄 Happy Holidays from Eisbach Bio! 🌟 As the year draws to a close, we at Eisbach Bio want to take a moment to extend our warmest wishes to you and your loved ones. 🎁❄️ May this holiday season be filled with joy, laughter, and cherished moments. ✨ We look forward to sharing more breakthroughs and innovations with you in the year ahead. 🚀 Happy holidays and seasons greetings from all of us at Eisbach Bio! ❄

Meet Eisbach Bio GmbH CEO Adrian Schomburg on October 20-24 at this year's ESMO Congress in Madrid to get an update on our drug discovery programs #Oncology #DrugDiscovery ESMO - European Society for Medical Oncology